Voyager Therapeutics (NASDAQ:VYGR) Cut to Buy at ValuEngine

Share on StockTwits

ValuEngine cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a strong-buy rating to a buy rating in a research report released on Monday, September 17th.

A number of other research firms have also recently commented on VYGR. Canaccord Genuity set a $35.00 price target on Voyager Therapeutics and gave the company a buy rating in a research note on Wednesday, June 6th. BTIG Research reiterated a buy rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research note on Thursday, June 7th. BidaskClub upgraded Voyager Therapeutics from a hold rating to a buy rating in a research note on Wednesday, June 6th. Chardan Capital reiterated a hold rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, June 21st. Finally, HC Wainwright began coverage on Voyager Therapeutics in a research note on Monday, June 4th. They issued a buy rating and a $30.00 price target for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $30.70.

Shares of NASDAQ VYGR traded up $0.43 during mid-day trading on Monday, reaching $16.13. 256,414 shares of the company were exchanged, compared to its average volume of 412,275. The stock has a market capitalization of $613.69 million, a P/E ratio of -6.11 and a beta of 2.94. Voyager Therapeutics has a 1 year low of $11.54 and a 1 year high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. The company had revenue of $2.58 million for the quarter, compared to analysts’ expectations of $3.00 million. Analysts predict that Voyager Therapeutics will post -3.12 EPS for the current year.

In other news, Director James A. Geraghty acquired 3,000 shares of Voyager Therapeutics stock in a transaction dated Monday, September 10th. The stock was purchased at an average cost of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the purchase, the director now directly owns 76,588 shares in the company, valued at approximately $1,485,041.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Glenn Pierce acquired 5,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, September 12th. The stock was purchased at an average price of $18.44 per share, with a total value of $92,200.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 11,000 shares of company stock valued at $205,300. Company insiders own 33.60% of the company’s stock.

Several large investors have recently made changes to their positions in VYGR. DekaBank Deutsche Girozentrale purchased a new position in shares of Voyager Therapeutics in the first quarter worth about $227,000. Trexquant Investment LP raised its stake in shares of Voyager Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 17,437 shares of the company’s stock worth $328,000 after purchasing an additional 6,687 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Voyager Therapeutics by 12.3% in the first quarter. Victory Capital Management Inc. now owns 81,890 shares of the company’s stock worth $1,539,000 after purchasing an additional 8,970 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Voyager Therapeutics by 12.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,727 shares of the company’s stock worth $1,630,000 after purchasing an additional 9,689 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Voyager Therapeutics by 85.9% in the first quarter. Neuberger Berman Group LLC now owns 20,240 shares of the company’s stock worth $380,000 after purchasing an additional 9,350 shares during the last quarter. Hedge funds and other institutional investors own 89.64% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Further Reading: What is a Fiduciary?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.